M&A / Deals Gilead Sciences completes Tubulis acquisition for $5bn Pharmaceutical TechnologyGilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn.Read full story pharminent May 22, 2026 (Last updated: May 22, 2026) Pharmaceutical Technology Gilead Sciences has concluded its acquisition of Germany-based biotechnology company Tubulis in a transaction valued at up to $5bn. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: In Alzheimer’s, Bristol Myers sees big promise beyond amyloidNext: GBL joins CVC in 10.7bn takeover bid for Recordati Related Stories M&A / Deals Sky-high Parabilis, Kailera IPOs spur optimism–but only for derisked biotechs pharminent June 11, 2026 M&A / Deals Aditxt and Ignite announce merger plans with strategic partner pharminent June 10, 2026 M&A / Deals Cancer biotech Parabilis books record IPO, raising $670m pharminent June 10, 2026
